Form 4: SERA CCO Anderson Receives Equity Awards

Sera Prognostics' Chief Commercial Officer, Dyaarl Lee Anderson Jr., was granted restricted stock units and stock options as part of his compensation.

Summary

• Dyaarl Lee Anderson Jr., Chief Commercial Officer of Sera Prognostics, Inc. (SERA), received equity awards on March 12, 2026.
• The awards include 12,455 Restricted Stock Units (RSUs) for Class A Common Stock, granted at a price of $0.
• The awards also include 19,310 stock options to purchase Class A Common Stock at an exercise price of $1.99 per share.
• The RSUs vest over four years, with 1/16 of the original grant amount vesting in quarterly installments following a vesting commencement date of March 10, 2026.
• The stock options vest over four years, with 1/48 of the original grant amount vesting in monthly installments following a vesting commencement date of March 10, 2026, and expire on March 12, 2036.
• Following these transactions, Anderson beneficially owns 79,569 Class A Common Stock and 19,310 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies the company's commitment to retaining and incentivizing a key executive, aligning their interests with long-term shareholder value, though it is a routine compensation event.

Positives

• The grant of equity awards aligns the Chief Commercial Officer's interests with those of shareholders, incentivizing long-term performance.
• The multi-year vesting schedule for both RSUs and stock options promotes executive retention and stability in leadership.

Negatives

• The grants do not provide immediate liquidity or cash compensation to the executive.
• Future exercise of options and conversion of RSUs could lead to some dilution for existing shareholders.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon the reporting person continuing to provide services to the issuer.

Future Outlook

The equity awards granted to the Chief Commercial Officer are structured with a multi-year vesting schedule, indicating an expectation of continued service and alignment with long-term company performance and strategic objectives.

Management Comments

• The grant of equity awards to the Chief Commercial Officer reflects the company's compensation strategy to incentivize long-term executive performance and retention.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the Chief Commercial Officer are a standard practice in the biotechnology and diagnostics industry, aiming to align executive incentives with shareholder value creation and retain critical talent in a competitive market.

Comparison to Industry Standards

• Equity compensation packages, including RSUs and stock options with multi-year vesting schedules, are a common practice across various industries, particularly in high-growth sectors like biotech, to attract and retain top talent.
• While specific comparable companies are not detailed in the filing, such grants are generally benchmarked against peer groups to ensure competitive compensation and motivate executives towards long-term company success.

Stakeholder Impact

• Shareholders: Potential for future dilution from the exercise of stock options and conversion of RSUs, balanced by improved alignment of executive incentives with long-term company performance.
• Employees: May signal stability in executive leadership and a commitment to competitive compensation practices.

Next Steps

• Quarterly vesting of 1/16 of the Restricted Stock Units over four years, commencing March 10, 2026.
• Monthly vesting of 1/48 of the stock options over four years, commencing March 10, 2026.
• Potential exercise of stock options by the expiration date of March 12, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard practice for executive compensation and retention. It does not present new information that would significantly alter the investment thesis for Sera Prognostics, hence a 'hold' recommendation is appropriate.

Keywords

Sera Prognostics, SERA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Chief Commercial Officer, Executive Compensation